Illinois Municipal Retirement Fund Has $2.29 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Illinois Municipal Retirement Fund trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 18.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,882 shares of the medical research company’s stock after selling 2,259 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in IQVIA were worth $2,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Lazard Asset Management LLC lifted its position in IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after acquiring an additional 80,189 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IQVIA by 3.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after purchasing an additional 77,422 shares during the period. Wellington Management Group LLP grew its holdings in IQVIA by 1.0% in the 3rd quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company’s stock valued at $357,350,000 after buying an additional 17,139 shares during the last quarter. JPMorgan Chase & Co. increased its position in IQVIA by 8.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,781,283 shares of the medical research company’s stock worth $350,467,000 after buying an additional 142,707 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of IQVIA by 1.8% during the third quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company’s stock worth $341,817,000 after buying an additional 31,413 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Barclays increased their target price on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Finally, BTIG Research assumed coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

Insiders Place Their Bets

In other news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Down 2.8 %

IQV opened at $234.08 on Friday. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a market cap of $42.49 billion, a price-to-earnings ratio of 32.11, a PEG ratio of 2.33 and a beta of 1.50. The firm’s 50-day simple moving average is $245.35 and its 200-day simple moving average is $222.77. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $2.54 earnings per share. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.